Exact Sciences, one of Madison’s largest biotech companies, may be sold to Abbott Laboratories, according to a report Wednesday by Bloomberg.

The new offensive coordinator says he didn't get his opening phone call in a normal spot, but it got him back to the place he made his name. Chad Morris was taking a photo of a seagull on a beach in ...

Recent Exact Sciences Corporation financials show accelerating revenue growth and stable margins, despite ongoing investments in screening and MRD. While EXAS maintains leadership in stool-based CRC ...

The latest announcement is out from Exact Sciences ( (EXAS)). On November 19, 2025, Exact Sciences Corporation agreed to be acquired by Abbott Laboratories through a merger in which Exact will become ...

Last month it was at the center of the year’s biggest health care transaction announcement, a deal worth more than $23 billion that includes the transformational technology to detect colon cancer ...

Abbott, a Chicago-based pharmaceutical company, is acquiring Madison-based biotechnology company Exact Sciences, which will become a subsidiary of Abbott, in a $21 billion deal, the companies ...

In case you've faced some hurdles solving the clue, Exact revenge, we've got the answer for you. Crossword puzzles offer a fantastic opportunity to engage your mind, enjoy leisure time, and test your ...

Abbott is getting into cancer testing with its $21 billion acquisition Exact Sciences, the maker of the game-changing colorectal cancer test Cologuard. Abbott markets well-known diagnostics for ...

Abbott’s roughly $21 billion acquisition of cancer screening firm Exact Sciences lays out the company’s future strategy. Analysts said the acquisition not only marks Abbott’s foray into cancer ...

Abbot Laboratory has announced a deal to acquire Madison-based Exact Sciences for approximately $21 billion. Exact Sciences, known for its Cologuard cancer screening test, was founded in 1995 and ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...